EHCM / Empirical Health Care Management

The ECHM project studies the role of innovation and regulation in health care markets and the related market reactions by health care providers. We aim to provide evidence to the following research questions: 

  • What is the impact of regulation on provider behavior in terms of technology diffusion and health care utilization?
  • Why are the most efficient technologies not used by health care systems?

We rely on empirical analyses using administrative or market research data and, survey based analyses. Study results contribute to a better understanding of market reactions from innovation and regulation in health care markets from the perspective of health policy and health care management.

Ongoing:

The impact of regulation at the regional level using the example of biosimilars

In 2006, the first biosimilar entered the German market. Today, the utilization rate of biosimilars varies largely across regions. Reason for the differing pace of diffusion and utilization could be divergent incentives to control health care spending, such as quotas or priority prescription regulations at regional level. In this project, we analyse the influence of meso-level regulation on physician prescribing behavior, which is part of the 2016 health services research initiative of the Central Research Institute of Ambulatory Health Care in Germany (Zi).

Collaborating and funding institution: Zentralinstitut für die Kassenärztliche Versorgung in Deutschland (Central Research Institute of Ambulatory Health Care in Germany (Zi))

Utilization and adoption of pharmaceuticals by physicians of ambulatory care

Physicians are typically faced with a multitude of influences when making choices to prescribe pharmaceuticals to patients. In this project, we study the role of information and regulation on utilization and adoption of health technology products. We account for different product types (e.g., new products, biosimilars, generics). We use econometric analyses to study the effects of varying information signals (reimbursement decisions) and the role of regulation (e.g., quotas, budgets) at different levels of the health care system.

Collaborating institutions: King's College London, Hamburg Center for health Economics

The impact of biomedical innovation on medication non-adherence

Medication non-adherence has been identified as substantial source of waste across health care systems. In this project, we study the influence of pharmaceutical innovation on adherence behavior in the working population in Germany and the United States. We focus on analyses of chronic conditions using real world data on drug utilization.

Collaborating institution: Columbia Business School, Columbia University, DocMorris

Completed:

Early benefit assessment of innovative pharmaceuticals according to AMNOG in Germany: empirical analysis of the decision-making process

By introducing the Act on the Reform of the Market for Medicinal Products (Arzneimittelmarktneuordnungsgesetz) in 2010, the regulatory framework for pharmaceuticals has changed for Germany. Manufacturers need to demonstrate a product’s health benefit and must negotiate prices accordingly. We aim to identify factors that determine the decision on added health benefit and prices. We differentiate between the quality of evidence, its presentation, technological characteristics, and process related aspects. We use a database of decisions and perform econometric analyses.

Collaborating institution: Hamburg Center for Health Economics, University of Hamburg